30.53 USD
-0.24 (-0.78%)
30.7 USD
+0.17 (+0.56%)
We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 530 industry peers in the Biotechnology industry. TGTX has an average financial health and profitability rating. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year TGTX was profitable.
TGTX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
TGTX has a better Return On Assets (43.65%) than 99.06% of its industry peers.
TGTX has a better Return On Equity (73.71%) than 99.25% of its industry peers.
TGTX has a Return On Invested Capital of 9.34%. This is amongst the best in the industry. TGTX outperforms 94.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.71% | ||
| ROIC | 9.34% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TGTX's Profit Margin of 84.11% is amongst the best of the industry. TGTX outperforms 98.49% of its industry peers.
TGTX's Operating Margin of 19.28% is amongst the best of the industry. TGTX outperforms 94.34% of its industry peers.
TGTX has a better Gross Margin (85.34%) than 87.74% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.28% | ||
| PM (TTM) | 84.11% | ||
| GM | 85.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TGTX is creating some value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
TGTX has a worse debt/assets ratio than last year.
2.2 Solvency
TGTX has an Altman-Z score of 6.87. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
TGTX has a Altman-Z score of 6.87. This is in the better half of the industry: TGTX outperforms 76.04% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that TGTX is not too dependend on debt financing.
The Debt to Equity ratio of TGTX (0.40) is worse than 70.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.87 |
ROIC/WACC1.06
WACC8.77%
2.3 Liquidity
TGTX has a Current Ratio of 3.82. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.82, TGTX perfoms like the industry average, outperforming 45.66% of the companies in the same industry.
A Quick Ratio of 2.89 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a Quick ratio of 2.89. This is in the lower half of the industry: TGTX underperforms 63.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 563.64% over the past year.
The Revenue has grown by 100.88% in the past year. This is a very strong growth!
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 364.59% on average per year.
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
3.2 Future
Based on estimates for the next years, TGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 92.99% on average per year.
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.43% yearly.
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TGTX is valuated quite expensively with a Price/Earnings ratio of 59.86.
90.38% of the companies in the same industry are more expensive than TGTX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.84, TGTX is valued quite expensively.
Based on the Price/Forward Earnings ratio of 16.37, the valuation of TGTX can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 95.47% of the companies listed in the same industry.
TGTX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.86 | ||
| Fwd PE | 16.37 |
4.2 Price Multiples
TGTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TGTX is cheaper than 90.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 48.15 |
4.3 Compensation for Growth
TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 157.07% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y265.02%
EPS Next 3Y157.07%
5. Dividend
5.1 Amount
No dividends for TGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
30.53
-0.24 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.63%
Inst Owner Change-3.01%
Ins Owners6.78%
Ins Owner Change-24.82%
Market Cap4.85B
Revenue(TTM)531.90M
Net Income(TTM)447.39M
Analysts78.67
Price Target45.17 (47.95%)
Short Float %16.96%
Short Ratio13.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.98%
Min EPS beat(2)-28.7%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-14.65%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)3
Avg EPS beat(8)0.93%
EPS beat(12)5
Avg EPS beat(12)39.18%
EPS beat(16)8
Avg EPS beat(16)34.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)4.19%
Revenue beat(4)3
Avg Revenue beat(4)1.06%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)4.47%
Revenue beat(12)9
Avg Revenue beat(12)25.49%
Revenue beat(16)11
Avg Revenue beat(16)25.09%
PT rev (1m)0%
PT rev (3m)5.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.81%
EPS NY rev (1m)277.08%
EPS NY rev (3m)267.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.54%
Revenue NY rev (1m)3.05%
Revenue NY rev (3m)2.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.86 | ||
| Fwd PE | 16.37 | ||
| P/S | 9.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.99 | ||
| P/tB | 7.99 | ||
| EV/EBITDA | 48.15 |
EPS(TTM)0.51
EY1.67%
EPS(NY)1.87
Fwd EY6.11%
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS3.35
BVpS3.82
TBVpS3.82
PEG (NY)0.03
PEG (5Y)N/A
Graham Number6.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.71% | ||
| ROCE | 11.82% | ||
| ROIC | 9.34% | ||
| ROICexc | 11% | ||
| ROICexgc | 11% | ||
| OM | 19.28% | ||
| PM (TTM) | 84.11% | ||
| GM | 85.34% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score5
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 348.98% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 4.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 | ||
| Altman-Z | 6.87 |
F-Score5
WACC8.77%
ROIC/WACC1.06
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
EBIT growth 1Y20410.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year378.75%
EBIT Next 3Y148.94%
EBIT Next 5YN/A
FCF growth 1Y-65.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.52%
OCF growth 3YN/A
OCF growth 5YN/A
TG THERAPEUTICS INC / TGTX FAQ
What is the fundamental rating for TGTX stock?
ChartMill assigns a fundamental rating of 5 / 10 to TGTX.
Can you provide the valuation status for TG THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.
Can you provide the profitability details for TG THERAPEUTICS INC?
TG THERAPEUTICS INC (TGTX) has a profitability rating of 6 / 10.
What are the PE and PB ratios of TG THERAPEUTICS INC (TGTX) stock?
The Price/Earnings (PE) ratio for TG THERAPEUTICS INC (TGTX) is 59.86 and the Price/Book (PB) ratio is 7.99.
How financially healthy is TG THERAPEUTICS INC?
The financial health rating of TG THERAPEUTICS INC (TGTX) is 4 / 10.